Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
70 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Octapharma (IP) from Anderlecht, company number BE0675901443, closed financial year 2025 with a result of € 5,089 after tax. For that financial year Octapharma (IP) recorded a gross margin of € 7,876 and equity of € 40,621. Compared with financial year 2024, the result moved from € 4,292 to € 5,089. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 10, 2026.
€ 40,621
▲ 14% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 5,089
▲ 19% vs 2024
Profit after tax over the fiscal year.
€ 56,302
▲ 25% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 28,221.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 6,881
▲ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 3,460
▲ 115% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 6,772 | € 5,813 | € 6,876 | € 7,876 | ▲ 15% |
| Profit after taxes | € 3,501 | € 3,602 | € 4,292 | € 5,089 | ▲ 19% |
| Equity | € 27,638 | € 31,241 | € 35,533 | € 40,621 | ▲ 14% |
| Total debts | € 366,948 | € 21,477 | € 9,393 | € 15,681 | ▲ 67% |
| Cash | - | € 4,945 | € 44,926 | € 56,302 | ▲ 25% |
| Retained profit | € 15,238 | € 18,841 | € 23,133 | € 28,221 | ▲ 22% |
| Balance sheet total | € 394,587 | € 52,718 | € 44,926 | € 56,302 | ▲ 25% |
Key figures of Octapharma (IP), fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Octapharma (IP)?
What happened at Octapharma (IP) in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 5,089 (▲ 19% vs 2024). filed late Source: NBB ↗
- New establishment in Anderlecht. KBO
- Start of the company according to the CBE. KBO
- Cornelius MARGUERRE became a director. NBB
- Daniel WYDER became a director. NBB
- Barbara RANGETINER became a director. NBB
- Norbert MÜLLER became a director. NBB
In short
From € 3,501 profit in 2022 to € 5,089 profit in 2025.
Paid € 6,179 in corporate taxes since 2022.
Best year ever: 2025, with € 5,089 profit.
A new publication or filing at Octapharma (IP)? We notify you, reason included.
Follow Octapharma (IP)Databakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Octapharma (IP) are Cornelius MARGUERRE, Daniel WYDER, Barbara RANGETINER and Norbert MÜLLER. Daniel WYDER is also behind OCTAPHARMA BENELUX.
Directors
According to the 2025 annual accounts
Cornelius MARGUERRE
Director
since 2017
since 2017
Barbara RANGETINER
Director
since 2017
Norbert MÜLLER
Director
since 2017
Establishments
Establishment units
Physical locations of this company
Lennikse Baan 451
1070 Anderlecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 70 companies are registered at this address.
All companies at this address →FISCHBEIN
€ 13.9 million revenue · 2025
HAIER BENELUX
€ 16.1 million revenue · 2025
PIRELLI TYRES BELUX
€ 3.6 million revenue · 2025
Ferring
€ 21.4 million revenue · 2023
HEALTH DATA MANAGEMENT PARTNERS
€ 1.5 million gross margin · 2025
+65 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0675.901.443
- VAT number
- BE 0675.901.443
- Registered office
- Lennikse Baan 451, 1070 Anderlecht
- Names & denominations
- Octapharma (IP)
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 May 2017
- Peppol
- Not registered